IJMSC: Recommendations to Address the Unique Clinical and Psychological Needs of Transgender Persons Living with Multiple Sclerosis

Release Date: February 1, 2022

Valid for Credit through: February 1, 2023

Activity Available Online:

To access the article, post-test, and evaluation online, go to

Target Audience:

The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, pharmacists, and other health care providers involved in the management of patients with multiple sclerosis (MS).

Learning Objectives:

  • Identify unique clinical and psychological care needs of transgender (TGD) MS patients
  • Describe best practice recommendations for the care of the TGD person living with MS


In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit:

The CMSC designates this journal-based activity for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Credit:

The CMSC designates this enduring material for .50 contact hour of nursing continuing professional development (NCPD) (none in the area of pharmacology).


Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), has served as a planner for this activity. He has disclosed relationships with Springer Publishing (royalty); Qr8 (receipt of intellectual property rights/patent holder); Biogen (receipt of intellectual property rights/patent holder, speakers’ bureau); MedRhythms (consulting fee, contracted research); GW Pharmaceuticals, Genentech, Helius Medical Technologies, Osmotica, Ipsen (consulting fee); and Adamas Pharmaceuticals (contracted research).

Alissa Mary Willis, MD, Associate Editor of IJMSC, has disclosed relationships with Greenwich Biosciences (consulting fee); Alexion (consulting fee, speakers’ bureau, contracted research); Genentech (consulting fee, speakers’ bureau); and Biogen, Bristol Myers Squibb (speakers’ bureau).


Amy Sullivan, PsyD has disclosed the following the following financial relationships: Consulting and Speakers Bureau: Novartis, Biogen, Bristol Myers Squibb and Genentech.

Alexa Kane, PsyD has disclosed no relevant financial relationships.

Gianna Valentic has disclosed no relevant financial relationships.

Mary Rensel, MD has disclosed the following financial relationships: Advisory Board: EMD Serono and Biogen; Research Support: Medimmune, Novartis and Genentech; Speaker’s Bureau: Novartis, Genzyme, and Biogen.

One peer reviewer for IJMSC has disclosed the following financial relationships: Consultant: Alexion, EMD Serono, Biogen, Novartis, Roche Genentech and Sanofi Genzyme; Research Support: Biogen, Novartis and Roche Genentech.

Two peer reviewers disclosed no relevant financial relationships.

The staff at IJMSC, CMSC, and Intellisphere, LLC who are in a position to influence content have disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP, Continuing Education Director CMSC, has served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships.

Note: Financial relationships may have changed in the interval between listing these disclosures and publication of the article.

Method of Participation:

Release Date: February 1, 2022; Valid for Credit through: February 1, 2023

In order to receive CE credit, participants must:

  1. Review the continuing education information, including learning objectives and author disclosures.
  2. Study the educational content.
  3. Complete the evaluation, which is available at

Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC and MJH Life Sciences do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or MJH Life Sciences.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.